AN2 Therapeutics, Inc. (ANTX) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts ANTX Hot Sheet
Join SI Premium – FREE
AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q4 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22).
For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chevron beats estimates as refining margins lift earnings
- OmniAb (OABI) Reports In-Line Q3 EPS
- Goldman Sachs Upgrades Chow Tai Fook Jewellery Group Ltd. (1929:HK) (CJEWF) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
